Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies

Home | About | Credits | Seminar List | Poster | Feedback

Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies
Brian Druker, March 2007
HHMI / Oregon Health & Science University Cancer Institute

Lecture Overview
Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. The first part of this lecture will describe the clinical features and the molecular pathogenesis of the disease for which imatinib was developed, chronic myeloid leukemia (CML). This overview will trace the history of the identification of the target of imatinib, BCR-ABL. The preclinical development of the BCR-ABL kinase inhibitor, imatinib and highly successful clinical trials of this agent for patients with CML will be reviewed along with the most up-to-date follow-up on these studies.
Part 1: Chronic Myeloid Leukemia (CML) and Imatinib (33:54)

Click image above to start seminar in 320x240 format
Click here to view in larger 640x480 format*
QuickTime 7 Required    *640x480 System Requirements
(there may be a few seconds delay before seminars start)

Downloads in alternative formats:
(To Save, Right Click a link below and select "Save Target/Link As")
QuickTime (63mb)     MP4 (378mb)     iPod Video (378mb)
PowerPoint Slides 1/page (867kb)     PowerPoint Slides 6/page (408kb)

Format Descriptions
Download Accelerator/Resume Broken Downloads Software

Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib (25:12)

Part 3: Extending the Imatinib Paradigm (22:09)

Speaker Bio    Related Articles

Disclaimers & Terms of Use
© 2008 The American Society for Cell Biology
8120 Woodmont Avenue Suite 750, Bethesda, MD 20814-2762
Phone: (301) 347-9300 Fax: (301) 347-9310

Lecture Overview Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. The first part of this lecture will describe the clinical features and the molecular pathogenesis of the disease for which imatinib was developed, chronic myeloid leukemia (CML). This overview will trace the history of the identification of the target of imatinib, BCR-ABL. The preclinical development of the BCR-ABL kinase inhibitor, imatinib and highly successful clinical trials of this agent for patients with CML will be reviewed along with the most up-to-date follow-up on these studies.	Part 1: Chronic Myeloid Leukemia (CML) and Imatinib (33:54) Click image above to start seminar in 320x240 format Click here to view in larger 640x480 format* QuickTime 7 Required 640x480 System Requirements (there may be a few seconds delay before seminars start) Downloads in alternative formats:* (To Save, Right Click a link below and select "Save Target/Link As") QuickTime (63mb) MP4 (378mb) iPod Video (378mb) PowerPoint Slides 1/page (867kb) PowerPoint Slides 6/page (408kb) Format Descriptions Download Accelerator/Resume Broken Downloads Software
Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib (25:12) Part 3: Extending the Imatinib Paradigm (22:09) Speaker Bio Related Articles